FOXP3 and allergic disease: Kim et al. proved that oral application of Lcr35 prevented the development of allergic disease by suppressing Th2, Th17, and thymic stromal lymphopoietin (TSLP) responses through a mechanism that may involve CD4+25+Foxp3+Tregs in MLNs [18].